Assura Plc (LON:AGR - Get Free Report)'s share price was up 11.6% during trading on Monday . The company traded as high as GBX 46.20 ($0.58) and last traded at GBX 43.52 ($0.55). Approximately 212,891,641 shares traded hands during trading, an increase of 1,382% from the average daily volume of 14,366,552 shares. The stock had previously closed at GBX 39 ($0.49).
The company has a market capitalization of £1.42 billion, a P/E ratio of -41.62, a P/E/G ratio of 3.60 and a beta of 0.37. The company has a current ratio of 0.89, a quick ratio of 2.84 and a debt-to-equity ratio of 85.05. The company has a 50 day moving average price of GBX 37.60 and a 200 day moving average price of GBX 39.70.
Assura (LON:AGR - Get Free Report) last released its earnings results on Thursday, November 14th. The real estate investment trust reported GBX 1.70 ($0.02) earnings per share for the quarter. Assura had a negative return on equity of 1.92% and a negative net margin of 18.09%. On average, equities analysts predict that Assura Plc will post 3.5830389 EPS for the current fiscal year.
The company also recently announced a dividend, which was paid on Wednesday, January 15th. Shareholders of record on Thursday, December 12th were given a dividend of GBX 0.84 ($0.01) per share. This represents a yield of 2.12%. The ex-dividend date was Thursday, December 12th. Assura's dividend payout ratio is presently -286.76%.
Assura plc is a specialist healthcare property investor and developer. We enable better health outcomes through our portfolio of more than 600 healthcare buildings across the UK and Ireland, from which over six million patients are served. We BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G). Assura plc achieved B Corp certification in July 2024 - the first FTSE 250 business to do so.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Assura, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assura wasn't on the list.
While Assura currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.